Anlotinib plus platinum‐etoposide as a first‐line treatment for extensive‐stage small cell lung cancer: A single‐arm trial

BACKGROUND: Anlotinib as a third‐line or beyond therapy for extensive‐stage small‐cell lung cancer (ES‐SCLC) was studied. This single‐arm phase II trial was to investigate the value of anlotinib plus platinum‐etoposide as first‐line treatment in ES SCLC. METHODS: The primary endpoint was progression...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Pengbo, Hu, Chengping, Chen, Cen, Cao, Liming, Gu, Qihua, An, Jian, Qin, Ling, Li, Min, He, Baimei, Jiang, Juan, Yang, Huaping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554443/
https://www.ncbi.nlm.nih.gov/pubmed/35526266
http://dx.doi.org/10.1002/cam4.4736

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554443/
https://www.ncbi.nlm.nih.gov/pubmed/35526266
http://dx.doi.org/10.1002/cam4.4736

Ejemplares similares